Please login to the form below

Not currently logged in
Email:
Password:

Neovii Pharmaceuticals promotes Juergen Pohle to CEO

He will take over from Alexandre Sudarskis in January

Neovii Pharmaceuticals Juergen PohleSwiss biopharmaceutical company Neovii Pharmaceuticals has promoted its chief commercial officer Juergen Pohle to managing director and CEO.

He will assume the new role in January, when it takes over from outgoing CEO Alexandre Sudarskis who will continue at the firm as an executive director and member of its board.

David Fuhrer said: "Juergen's leadership skills, his long-term proven track record and his many years of international experience in the pharmaceutical industry make him the ideal candidate for the position of CEO.

“We are extremely pleased that Juergen has embraced the challenge of further driving the development and growth of Neovii."

Pohle has served as Neovii’s chief commercial officer of Pharmaceuticals since 2016 and has over 25 years of experience in the pharmaceutical industry, having previously worked at Bayer HealthCare, GlaxoSmithKline and Novartis.

Prior to joining Neovii he headed up Novartis’ emerging growth markets and institutional customers businesses.

18th September 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...